 | Up a level |
Estenfelder, S., Tausch, E., Huber, H., Bloehdorn, J., Cymbalista, F., Leblond, V., Delmer, A., Ibach, S., Choquet, S., Dartigeas, C., Cazin, B., Tournilhac, O., Pegourie, B., Seiler, T., Soekler, M., Zirlik, K., Alt, J., Schetelig, J., Hallek, M., Dreger, P., Doehner, H. and Stilgenbauer, S. (2016). MUTATION ANALYSIS BY TARGETED NEXT GENERATION SEQUENCING IN ULTRA HIGH RISK CLL PATIENTS TREATED WITHIN THE CLL2O STUDY. Haematologica, 101. S. 228 - 230. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Faehling, M., Schumann, C., Christopoulos, P., Hoffknecht, P., Alt, J., Horn, M., Eisenmann, S., Schlenska-Lange, A., Aries, S. P., Sackmann, S., Schuett, P., Steger, F. and Christoph, D. (2020). Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC: Real-world data on survival and safety from the German expanded access program (EAP). Ann. Oncol., 31. S. S806 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Frost, N., Christopoulos, P., Kauffmann-Guerrero, D., Stratmann, J. A., Riedel, R., Schaefer, M., Alt, J., Guetz, S., Brinkmann, J. and Griesinger, F. (2020). Lorlatinib in pretreated ALK/ROS1-positive non-small cell lung cancer (NSCLC): Results from the German early access program. Ann. Oncol., 31. S. S874 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Janning, M., Sueptitz, J., Albers-Leischner, C., Delpy, P., Tufman, A., Velthaus-Rusik, J-L, Reck, M., Jung, A., Kauffmann-Guerrero, D., Bonzheim, I, Braendlein, S., Hummel, H-D, Wiesweg, M., Schildhaus, H-U, Stratmann, J. A., Sebastian, M., Alt, J., Buth, J., Esposito, I, Berger, J., Toegel, L., Saalfeld, F. C., Wermke, M., Merkelbach-Bruse, S., Hillmer, A. M., Klauschen, F., Bokemeyer, C., Buettner, R., Wolf, J. and Loges, S. (2022). Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNuM). Ann. Oncol., 33 (6). S. 602 - 616. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Stratmann, J. A., Hornetz, S., Griesinger, F., Wolf, J., Christoph, D. C., Sackmann, S., Spengler, W., Bischoff, H., Schaefer, M., Alt, J., Mlueller, A., Laack, E., Kimmich, M. and Sebastian, M. (2017). An expanded access program of osimertinib (Tagrisso) in patients with advanced non-small cell lung cancer: data report from Germany. Oncol. Res. Treat., 40. S. 170 - 171. BASEL: KARGER. ISSN 2296-5262